Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
Information source: Stanford University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetic Nephropathy
Intervention: Addition of furosemide 20 mg oral bid to baseline regimen (Drug)
Phase: N/A
Status: Completed
Sponsored by: Stanford University Official(s) and/or principal investigator(s):
Timothy W Meyer, MD, Principal Investigator, Affiliation: Stanford University
Summary
The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with
diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent
(furosemide) will decrease the urine protein, which is a sign of disease, more than an
angiotensin converting enzyme inhibitor alone.
Clinical Details
Official title: Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study
Primary outcome: The amount of protein in the urine after 8 weeks of treatment.
Secondary outcome: The estimated glomerular filtration rate after 8 weeks of treatment.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
proteinuria greater than 1 gram/day serum creatinine < 2. 6 for men, < 2. 0 for women
Exclusion Criteria:
blood pressure which cannot be controlled without a diuretic renal diseases other than
diabetic nephropathy other disease which would alter renal function during 6 months
Locations and Contacts
Stanford University Medical Center, Stanford, California 94305, United States
Kaiser Permanente of Northern California, Santa Clara and San Jose, Santa Clara, California 95051, United States
Additional Information
Starting date: December 2003
Ending date: April 2006
Last updated: October 16, 2006
|
